Home » Stocks » BLUE

Bluebird Bio, Inc. (BLUE)

Stock Price: $34.10 USD 0.21 (0.62%)
Updated Jun 11, 2021 4:00 PM EDT - Market closed
After-hours: $34.00 -0.10 (-0.29%) Jun 11, 5:50 PM
Market Cap 2.30B
Revenue (ttm) 241.67M
Net Income (ttm) -621.89M
Shares Out 67.45M
EPS (ttm) -9.56
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day June 11
Last Price $34.10
Previous Close $33.89
Change ($) 0.21
Change (%) 0.62%
Day's Open 34.25
Day's Range 33.30 - 34.37
Day's Volume 1,249,014
52-Week Range 24.24 - 68.39

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BLUE--bluebird bio, Inc. (Nasdaq: BLUE) today presented data from several studies of betibeglogene autotemcel (beti-cel) gene therapy (licensed as ZYNTEGLO™ in the...

1 day ago - Business Wire

We believe that the stock price of bluebird bio (NASDAQ: BLUE), a biotechnology company focused on gene therapies for severe genetic disorders and cancer, looks attractive at current levels of around $3...

3 days ago - Forbes

The FDA lifts the clinical hold on bluebird's (BLUE) studies on LentiGlobin for sickle cell disease and betibeglogene autotemcel for transfusion-dependent thalassemia. Shares rise.

4 days ago - Zacks Investment Research

The FDA has lifted the hold on bluebird bio's gene-therapy studies in sickle cell disease and transfusion-dependent β-thalassemia.

5 days ago - The Motley Fool

CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) today announced that members of the management team will participate in the Goldman Sachs 42nd Annual Global Healthcare Conference, T...

5 days ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BLUE--bluebird bio, Inc. (Nasdaq: BLUE) today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical holds on the Phase 1/2 HGB-206 and...

5 days ago - Business Wire

Bluebird (BLUE) reported earnings 30 days ago. What's next for the stock?

1 week ago - Zacks Investment Research

CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) today announced that the Compensation Committee of the Company's Board of Directors approved inducement grants of stock options to pu...

1 week ago - Business Wire

With the stock down 54% over the past year, will investors be catching a falling knife if they buy now?

2 weeks ago - The Motley Fool

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended marketing authorizations for Bluebird bio Inc's (NASDAQ: BLUE) Skysona (elivaldogene autotemcel) new...

3 weeks ago - Benzinga

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BLUE--bluebird bio, Inc. (Nasdaq: BLUE) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopt...

3 weeks ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BLUE--bluebird bio, Inc. (Nasdaq: BLUE) announced today that data from its gene therapy programs for transfusion-dependent β-thalassemia (TDT) and sickle cell dise...

4 weeks ago - Business Wire

bluebird (BLUE) reports a wider-than-expected loss for the first quarter of 2021 while revenues beat estimates.

1 month ago - Zacks Investment Research

Bluebird (BLUE) delivered earnings and revenue surprises of -0.66% and 19.44%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) today reported financial results and business highlights for the first quarter ended March 31, 2021 and shared recent operational pro...

1 month ago - Business Wire

Bluebird (BLUE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago - Zacks Investment Research

CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) today announced that members of the management team will participate in the following upcoming investor conferences: BofA Securities ...

1 month ago - Business Wire

Abecma is on the market.

Other stocks mentioned: BMY
1 month ago - The Motley Fool

The competition is starting to heat up, but bluebird is far from finished.

1 month ago - The Motley Fool

CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) announced today business and program updates across its severe genetic disease portfolio including a revised diagnosis for the previo...

1 month ago - Business Wire

OXFORD, England & CAMBRIDGE, Mass.--(BUSINESS WIRE)--PsiOxus Therapeutics and bluebird bio, Inc. presented preclinical data at the American Association for Cancer Research (AACR) Annual Meeting 2021.

1 month ago - Business Wire

The biotech has had a rough couple of years.

1 month ago - The Motley Fool

New York, New York--(Newsfile Corp. - April 13, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of blu...

1 month ago - Newsfile Corp

Los Angeles, California--(Newsfile Corp. - April 13, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against bluebird bio, Inc. ("...

1 month ago - Newsfile Corp

New York, New York--(Newsfile Corp. - April 13, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of bluebird bio, Inc. (NASDAQ: BLUE) between May 11, ...

1 month ago - Newsfile Corp

New York, New York--(Newsfile Corp. - April 13, 2021) - Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against bluebird bio, Inc. ("bluebird" or the "Co...

1 month ago - Newsfile Corp

New York, New York--(Newsfile Corp. - April 12, 2021) -  The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of bluebird bio, Inc. (NASDAQ: BLUE) alleging...

2 months ago - Newsfile Corp

LOS ANGELES, April 12, 2021 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against bluebird bio, Inc. ("bluebird" or "the...

2 months ago - PRNewsWire

NEW YORK, April 12, 2021 /PRNewswire/ -- Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline for investors to file a lead plaintiff motion in a securit...

2 months ago - PRNewsWire

New York, New York--(Newsfile Corp. - April 12, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of bluebird bio, Inc. (NASDAQ: BLUE) between May 11, ...

2 months ago - Newsfile Corp

Los Angeles, California--(Newsfile Corp. - April 12, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against bluebird bio, Inc. ("...

2 months ago - Newsfile Corp

New York, New York--(Newsfile Corp. - April 9, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of bluebird bio, Inc. (NASDAQ: BLUE) alleging t...

2 months ago - Newsfile Corp

New York, New York--(Newsfile Corp. - April 9, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of blue...

2 months ago - Newsfile Corp

Los Angeles, California--(Newsfile Corp. - April 9, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against bluebird bio, Inc. ("b...

2 months ago - Newsfile Corp

LOS ANGELES--(BUSINESS WIRE)---- $BLUE #investors--The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against bluebird bio, Inc. (BLUE)

2 months ago - Business Wire

New York, New York--(Newsfile Corp. - April 8, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of blue...

2 months ago - Newsfile Corp

Los Angeles, California--(Newsfile Corp. - April 8, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against bluebird bio, Inc. ("b...

2 months ago - Newsfile Corp

An artificial intelligence system identifying high-potential equities has been on the mark in 2021. Here are its 10 top stocks to watch over the next few months.

Other stocks mentioned: AAL, ALB, ALK, EBIX, FTI, NIO, PLTR ...
2 months ago - Kiplinger

NEW YORK, April 6, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against bluebird bio, Inc. ("bluebird" or the "Company") (NASDAQ: BLUE) and certain of its offi...

2 months ago - PRNewsWire

New York, New York--(Newsfile Corp. - April 4, 2021) - Pomerantz LLP announces that a class action lawsuit has been filed against bluebird bio, Inc. ("bluebird" or the "Company") (NASDAQ: BLUE) and cert...

2 months ago - Newsfile Corp

New York, New York--(Newsfile Corp. - April 3, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of bluebird bio, Inc. (NASDAQ: BLUE) between May 11, 2...

2 months ago - Newsfile Corp

New York, New York--(Newsfile Corp. - April 2, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of blue...

2 months ago - Newsfile Corp

NEW YORK, March 31, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against bluebird bio, Inc. ("bluebird" or the "Company") (NASDAQ: BLUE) and certain of its off...

2 months ago - PRNewsWire

New York, New York--(Newsfile Corp. - March 29, 2021) - Pomerantz LLP announces that a class action lawsuit has been filed against bluebird bio, Inc. ("bluebird" or the "Company") (NASDAQ: BLUE) and cer...

2 months ago - Newsfile Corp

Investors reacted positively to a key FDA approval.

2 months ago - The Motley Fool

Humanigen, Inc. (NASDAQ: HGEN), uniQure N.V. (NASDAQ: QURE), bluebird bio, Inc. (NASDAQ: BLUE) and Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) were among the biotech gainers on Monday.

Other stocks mentioned: HGEN, QURE, AMPH
2 months ago - Benzinga

Bluebird (BLUE) reported earnings 30 days ago. What's next for the stock?

2 months ago - Zacks Investment Research

Though these stocks have dropped, upcoming news offers hope for them to rebound.

Other stocks mentioned: SAGE, TRIL
2 months ago - The Motley Fool

New York, New York--(Newsfile Corp. - March 24, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of blu...

2 months ago - Newsfile Corp

NEW YORK, March 24, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against bluebird bio, Inc. ("bluebird" or the "Company") (NASDAQ: BLUE) and certain of its off...

2 months ago - PRNewsWire

About BLUE

bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases and cancer. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; LentiGlobin for the treatment of sickle cell disease; and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy. The company's product candidates in oncology include Idecabtagene vicleucel and bb21217, which are chimeric antigen receptor T (C... [Read more...]

Industry
Biotechnology
IPO Date
Jun 19, 2013
Stock Exchange
NASDAQ
Ticker Symbol
BLUE
Full Company Profile

Financial Performance

In 2020, Bluebird Bio's revenue was $250.73 million, an increase of 461.25% compared to the previous year's $44.67 million. Losses were -$618.70 million, -21.65% less than in 2019.

Financial Statements

Analyst Forecasts

According to 24 analysts, the average rating for Bluebird Bio stock is "Buy." The 12-month stock price forecast is 49.00, which is an increase of 43.70% from the latest price.

Price Target
$49.00
(43.70% upside)
Analyst Consensus: Buy